Futura Medical Regulatory News (FUM)

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, AUSTRALIA, THE REPUBLIC OF IRELAND, NEW ZEALAND OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN FUTURA MEDICAL PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF FUTURA MEDICAL PLC.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014.

Unless otherwise indicated defined terms used in this announcement have the same meaning as those terms defined and used in the circular published in connection with the Fundraising, dated 24 October 2018.

Result of Open Offer General Meeting & Total Voting Rights

12 November 2018

On 19 October 2018 Futura Medical plc (AIM: FUM) (the "Company), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announced that it had conditionally raised c. £5.6 million in aggregate before fees and expenses through a successful Placing, Subscription and PrimaryBid Offer with certain existing and new institutional and other investors at the Placing Price of 7 pence per share. The Company today announces that it has conditionally raised further additional gross proceeds of £0.25 million in aggregate from the Open Offer.

The Company is also pleased to announce that at the General Meeting held today, all Resolutions proposed were duly passed. The Fundraising remains conditional on, inter alia, Admission.

The Open Offer closed for acceptances at 11.00 a.m. on 9 November 2018. Valid acceptances have been received in respect of 3,577,437 Open Offer Shares. All valid applications under the Open Offer will accordingly be satisfied in full. Accordingly, the Open Offer has conditionally raised gross proceeds of c. £0.25 million, and the Company has therefore conditionally raised total gross proceeds of £5.85 million from the Fundraising and will issue a total of 83,577,437 new Ordinary Shares in connection with the fundraise (the "Fundraising Shares").

Application has been made to the London Stock Exchange for the Fundraising Shares to be admitted to trading on AIM. It is expected that Admission will become effective, and that dealings in the Fundraising Shares will commence, at 8.00 a.m. on 13 November 2018.

For the purposes of the FCA's Disclosure Guidance and Transparency Rules (DTR), the Company's total voting rights as from the date of Admission will be 204,583,439 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,583,439 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's DTR.

This announcement should be read in conjunction with the full text of the circular dated 24 October 2018, published in connection with the Fundraising.

ENDS

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Broker:N+1 SingerAubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 20 3950 9144

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

Important Notice

N+1 Singer is acting as nominated adviser and broker and as agent for and on behalf of the Company for the Placing. N+1 Singer is authorised and regulated by the Financial Conduct Authority (the "FCA") in the United Kingdom. N+1 Singer is not acting for the Company in relation to the PrimaryBid Offer. N+1 Singer is acting exclusively for the Company and no one else in connection with the Placing and N+1 Singer will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this announcement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by N+1 Singer or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

No statement in this announcement is intended to be a profit forecast or estimate, and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The Placing Shares, Subscription Shares, PrimaryBid Shares and the Open Offer Shares will not be admitted to trading on any stock exchange other than on the AIM market of the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.